NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Fritsch S, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W, Spiekermann K.
Schneider F, et al. Among authors: bohlander sk.
Blood. 2009 May 21;113(21):5250-3. doi: 10.1182/blood-2008-09-172668. Epub 2009 Mar 11.
Blood. 2009.
PMID: 19279329
Free article.